Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Pipeline Review, H1 2017

June 2017 | 26 pages | ID: M43B26E06EDEN
Global Markets Direct

Abstracts

Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Pipeline Review, H1 2017

SUMMARY

Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Mitogen-activated protein kinase 9 is an enzyme that is encoded by the MAPK9 gene. This kinase targets specific transcription factors and thus mediates immediate-early gene expression in response to various cell stimuli. This kinase blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells.

Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Oncology which include indications Parkinson's Disease, Atherosclerosis, Breast Cancer and Multiple Sclerosis.

The latest report Mitogen Activated Protein Kinase 9 - Pipeline Review, H1 2017, outlays comprehensive information on the Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24)
• The report reviews Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
• The report assesses Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Eisai Co Ltd
OPKO Health Inc
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Drug Profiles
ER-358063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JNK1, JNK2 and JNK3 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-3306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Eisai Co Ltd, H1 2017
Pipeline by OPKO Health Inc, H1 2017
Dormant Projects, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Eisai Co Ltd
OPKO Health Inc